CER Daily Newsfeed

Value Viewpoint: October 31, 2025

(10/31, Kimberly Westrich, LinkedIn) comments “This week, NPC submitted comments on the Health Economics Methods Advisory (HEMA) group’s draft report titled ‘Defining Appropriate Benefits for Economic Evaluation of Health Care Technologies.’ Unfortunately, the draft report represents a missed opportunity to advance evidence-based, patient-focused HTA methods. NPC’s key concerns and associated recommendations for this report include: 1. The proposed principles reinforce existing HTA practices and often assume the status quo as the gold standard...2. The proposed ‘opportunity cost’ principle is not operational within the U.S. healthcare system and relies on weak evidence...3. Economic evaluations must be viewed as a tool, not a rule.” Full

Finerenone vs Spironolactone in Kidney Disease Trial

(10/31, Bioengineer.org) reports “...This research, published in Nature Communications by Wang et al., presents a compelling target trial emulation to directly contrast the efficacy and safety profiles of these drugs, potentially redefining therapeutic strategies for millions affected globally by these intertwined conditions...By artfully emulating clinical trial conditions, the investigators surmounted the ethical and logistical limitations associated with enrolling large cohorts in direct comparative trials, while preserving validity and minimizing confounding.” Full

Bryant-Moore Named Chair of Advisory Board for National Organization

(11/3, Kev' Moye, UAMS News) reports “Keneshia Bryant-Moore, Ph.D., APRN, will serve as chair of the patient engagement advisory panel (PEAP) for the Patient-Centered Outcomes Research Institute...‘It’s my heart’s passion to make sure that voices, which aren’t normally heard, are being brought to the forefront,’ she said. ‘I prefer for people to share their own voice. But if not, I want to be a source to help them magnify their voice.’” Full

Insights from the AMCP Nexus 2025 Meeting

(11/3, Denise Myshko, Managed Healthcare Executive) reports “...AMCP is working with stakeholders to address the challenges for integrating real-world evidence into healthcare decision-making. By the first quarter of 2026, AMCP plans to launch a map for RWE Integration into Formulary Evaluation. This year, the organization developed a standards document to better align payers and pharmaceutical companies on understanding and applying real-world evidence.” Full

New CBO Report Confirms 340B’s Ballooning Costs. Congress must Act.

(10/31, Dan Crippen, Healthcare Dive) comments “...The CBO has now done what both Congress and the Executive have avoided for years: evaluated the size, scope, and consequences of a program long overdue for reform. With this report in hand, Congress has no excuse to look the other way. If its goal is to lower healthcare spending and increase tax revenue, reducing 340B subsidies fits the bill.” Full

Video: Mayo Clinic Labs CEO: Diagnostics Drive a New Era of Precision Medicine

(11/3, Fierce Healthcare) reports “...In a conversation with Fierce Biotech Publisher Rebecca Willumson, William Morice II, M.D., Ph.D. , president and CEO of Mayo Clinic Laboratories, said advances in diagnostic testing are allowing clinicians to target therapies based on the underlying biology of disease. From cancer care to immune system response, precision diagnostics are helping doctors deliver more effective and personalized treatments. Morice said the next wave of innovation will come from harnessing the massive amount of data diagnostics generate.” Full